Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
[What do physicians expect from nurses in the future society?].

Sygeplejersken

Holm-Nielsen P.
PMID: 4490162
Sygeplejersken. 1973 May 31;73(18):4-7.

No abstract available.

Cite
Holm-Nielsen P. Hvad venter laegen af sygeplejersken i det kommende samfund. [What do physicians expect from nurses in the future society?]. Sygeplejersken. 1973;73(18):4-7
Holm-Nielsen, P. (1973). Hvad venter laegen af sygeplejersken i det kommende samfund. [What do physicians expect from nurses in the future society?]. Sygeplejersken, 73(18), 4-7.
Holm-Nielsen, P. "Hvad venter laegen af sygeplejersken i det kommende samfund." [What do physicians expect from nurses in the future society?]. Sygeplejersken vol. 73,18 (1973): 4-7.
Holm-Nielsen P. Hvad venter laegen af sygeplejersken i det kommende samfund. [What do physicians expect from nurses in the future society?]. Sygeplejersken. 1973 May 31;73(18):4-7. Danish. PMID: 4490162.
Copy Download .nbib Format: NLM
A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis.

Biochemistry and biophysics reports

Leeming DJ, Willumsen N, Sand JMB, Holm Nielsen S, Dasgupta B, Brodmerkel C, Curran M, Bager CL, Karsdal MA.
PMID: 30555938
Biochem Biophys Rep. 2018 Nov 30;17:38-43. doi: 10.1016/j.bbrep.2018.11.002. eCollection 2019 Mar.

OBJECTIVES: Lysyl oxidase like 2 (LOXL2) is associated with poor prognosis in idiopathic pulmonary disease (IPF) and cancer. We developed an Enzyme-linked immunosorbent assay (ELISA) targeting the LOXL2 neo-epitope generated through the release of the signal peptide during LOXL2...

Cite
Leeming DJ, Willumsen N, Sand JMB, et al. A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochem Biophys Rep. 2018;17:38-43doi: 10.1016/j.bbrep.2018.11.002.
Leeming, D. J., Willumsen, N., Sand, J. M. B., Holm Nielsen, S., Dasgupta, B., Brodmerkel, C., Curran, M., Bager, C. L., & Karsdal, M. A. (2019). A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochemistry and biophysics reports, 1738-43. https://doi.org/10.1016/j.bbrep.2018.11.002
Leeming, D J, et al. "A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis." Biochemistry and biophysics reports vol. 17 (2019): 38-43. doi: https://doi.org/10.1016/j.bbrep.2018.11.002
Leeming DJ, Willumsen N, Sand JMB, Holm Nielsen S, Dasgupta B, Brodmerkel C, Curran M, Bager CL, Karsdal MA. A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis. Biochem Biophys Rep. 2018 Nov 30;17:38-43. doi: 10.1016/j.bbrep.2018.11.002. eCollection 2019 Mar. PMID: 30555938; PMCID: PMC6276730.
Copy Download .nbib Format: NLM
Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes.

Clinical biochemistry

Karsdal MA, Genovese F, Rasmussen DGK, Bay-Jensen AC, Mortensen JH, Holm Nielsen S, Willumsen N, Jensen C, Manon-Jensen T, Jennings L, Reese-Petersen AL, Henriksen K, Sand JM, Bager C, Leeming DJ.
PMID: 34453894
Clin Biochem. 2021 Nov;97:11-24. doi: 10.1016/j.clinbiochem.2021.08.007. Epub 2021 Aug 26.

OBJECTIVES: There is a need for precision medicine and an unspoken promise of an optimal approach for identification of the right patients for value-based medicine based on big data. However, there may be a misconception that measurement of proteins...

Cite
Karsdal MA, Genovese F, Rasmussen DGK, et al. Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clin Biochem. 2021;97:11-24doi: 10.1016/j.clinbiochem.2021.08.007.
Karsdal, M. A., Genovese, F., Rasmussen, D. G. K., Bay-Jensen, A. C., Mortensen, J. H., Holm Nielsen, S., Willumsen, N., Jensen, C., Manon-Jensen, T., Jennings, L., Reese-Petersen, A. L., Henriksen, K., Sand, J. M., Bager, C., & Leeming, D. J. (2021). Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clinical biochemistry, 9711-24. https://doi.org/10.1016/j.clinbiochem.2021.08.007
Karsdal, M A, et al. "Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes." Clinical biochemistry vol. 97 (2021): 11-24. doi: https://doi.org/10.1016/j.clinbiochem.2021.08.007
Karsdal MA, Genovese F, Rasmussen DGK, Bay-Jensen AC, Mortensen JH, Holm Nielsen S, Willumsen N, Jensen C, Manon-Jensen T, Jennings L, Reese-Petersen AL, Henriksen K, Sand JM, Bager C, Leeming DJ. Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. Clin Biochem. 2021 Nov;97:11-24. doi: 10.1016/j.clinbiochem.2021.08.007. Epub 2021 Aug 26. PMID: 34453894.
Copy Download .nbib Format: NLM
Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients.

Journal of hepatocellular carcinoma

Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N.
PMID: 33204663
J Hepatocell Carcinoma. 2020 Nov 09;7:301-313. doi: 10.2147/JHC.S275008. eCollection 2020.

PURPOSE: Non-invasive biomarkers for diagnosing and prognosing hepatocellular carcinoma (HCC) are urgently needed. Cirrhosis is present in 80-90% of HCC patients. Cirrhosis is characterized by deposition and cross-linking of collagens that have crucial roles in HCC initiation and progression....

Cite
Jensen C, Holm Nielsen S, Eslam M, et al. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma. 2020;7:301-313doi: 10.2147/JHC.S275008.
Jensen, C., Holm Nielsen, S., Eslam, M., Genovese, F., Nielsen, M. J., Vongsuvanh, R., Uchila, R., van der Poorten, D., George, J., Karsdal, M. A., Leeming, D. J., & Willumsen, N. (2020). Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. Journal of hepatocellular carcinoma, 7301-313. https://doi.org/10.2147/JHC.S275008
Jensen, Christina, et al. "Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients." Journal of hepatocellular carcinoma vol. 7 (2020): 301-313. doi: https://doi.org/10.2147/JHC.S275008
Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma. 2020 Nov 09;7:301-313. doi: 10.2147/JHC.S275008. eCollection 2020. PMID: 33204663; PMCID: PMC7665576.
Copy Download .nbib Format: NLM
Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone.

Pulmonary circulation

Andersen S, Birkmose Axelsen J, Ringgaard S, Randel Nyengaard J, Holm Nielsen S, Genovese F, Asser Karsdal M, Adler Hyldebrandt J, Brandt Sørensen C, de Man FS, Jan Bogaard H, Erik Nielsen-Kudsk J, Andersen A.
PMID: 30997866
Pulm Circ. 2019 Apr-Jun;9(2):2045894019848659. doi: 10.1177/2045894019848659.

Cardiac fibrosis contributes to the development of heart failure in pulmonary hypertension. We aimed to assess the development of fibrosis and the effects of treatment with the anti-fibrotic agent pirfenidone in pressure overload induced right ventricular (RV) failure. Wistar...

Cite
Andersen S, Birkmose Axelsen J, Ringgaard S, et al. Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone. Pulm Circ. 2019;9(2):2045894019848659doi: 10.1177/2045894019848659.
Andersen, S., Birkmose Axelsen, J., Ringgaard, S., Randel Nyengaard, J., Holm Nielsen, S., Genovese, F., Asser Karsdal, M., Adler Hyldebrandt, J., Brandt Sørensen, C., de Man, F. S., Jan Bogaard, H., Erik Nielsen-Kudsk, J., & Andersen, A. (2019). Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone. Pulmonary circulation, 9(2), 2045894019848659. https://doi.org/10.1177/2045894019848659
Andersen, Stine, et al. "Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone." Pulmonary circulation vol. 9,2 (2019): 2045894019848659. doi: https://doi.org/10.1177/2045894019848659
Andersen S, Birkmose Axelsen J, Ringgaard S, Randel Nyengaard J, Holm Nielsen S, Genovese F, Asser Karsdal M, Adler Hyldebrandt J, Brandt Sørensen C, de Man FS, Jan Bogaard H, Erik Nielsen-Kudsk J, Andersen A. Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone. Pulm Circ. 2019 Apr-Jun;9(2):2045894019848659. doi: 10.1177/2045894019848659. PMID: 30997866; PMCID: PMC6540527.
Copy Download .nbib Format: NLM
Electricity consumption data of a student residence in Southern Africa.

Data in brief

Masebinu SO, Holm-Nielsen JB, Mbohwa C, Padmanaban S, Nwulu N.
PMID: 32904363
Data Brief. 2020 Aug 08;32:106150. doi: 10.1016/j.dib.2020.106150. eCollection 2020 Oct.

The time-series dataset presented in this article was captured using a real-time energy monitoring device from a distribution panel of a student residence in Johannesburg, South Africa. The data was captured from April 2016 to January 2018. The data...

Cite
Masebinu SO, Holm-Nielsen JB, Mbohwa C, et al. Electricity consumption data of a student residence in Southern Africa. Data Brief. 2020;32:106150doi: 10.1016/j.dib.2020.106150.
Masebinu, S. O., Holm-Nielsen, J. B., Mbohwa, C., Padmanaban, S., & Nwulu, N. (2020). Electricity consumption data of a student residence in Southern Africa. Data in brief, 32106150. https://doi.org/10.1016/j.dib.2020.106150
Masebinu, S O, et al. "Electricity consumption data of a student residence in Southern Africa." Data in brief vol. 32 (2020): 106150. doi: https://doi.org/10.1016/j.dib.2020.106150
Masebinu SO, Holm-Nielsen JB, Mbohwa C, Padmanaban S, Nwulu N. Electricity consumption data of a student residence in Southern Africa. Data Brief. 2020 Aug 08;32:106150. doi: 10.1016/j.dib.2020.106150. eCollection 2020 Oct. PMID: 32904363; PMCID: PMC7452690.
Copy Download .nbib Format: NLM
Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders.

Translational oncology

Holm Nielsen S, Willumsen N, Leeming DJ, Daniels SJ, Brix S, Karsdal MA, Genovese F, Nielsen MJ.
PMID: 30504086
Transl Oncol. 2019 Feb;12(2):368-374. doi: 10.1016/j.tranon.2018.11.004. Epub 2018 Nov 30.

OBJECTIVES: Remodeling of the extracellular matrix (ECM) is a key event in different lung disorders, such as fibrosis and cancer. The most common cell type in the connective tissue is fibroblasts, which transdifferentiate into myofibroblasts upon activation. All myofibroblasts...

Cite
Holm Nielsen S, Willumsen N, Leeming DJ, et al. Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders. Transl Oncol. 2018;12(2):368-374doi: 10.1016/j.tranon.2018.11.004.
Holm Nielsen, S., Willumsen, N., Leeming, D. J., Daniels, S. J., Brix, S., Karsdal, M. A., Genovese, F., & Nielsen, M. J. (2019). Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders. Translational oncology, 12(2), 368-374. https://doi.org/10.1016/j.tranon.2018.11.004
Holm Nielsen, Signe, et al. "Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders." Translational oncology vol. 12,2 (2019): 368-374. doi: https://doi.org/10.1016/j.tranon.2018.11.004
Holm Nielsen S, Willumsen N, Leeming DJ, Daniels SJ, Brix S, Karsdal MA, Genovese F, Nielsen MJ. Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (α-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders. Transl Oncol. 2019 Feb;12(2):368-374. doi: 10.1016/j.tranon.2018.11.004. Epub 2018 Nov 30. PMID: 30504086; PMCID: PMC6277250.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries